[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.175.236. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
December 2013

Rotavirus Vaccines, Intussusception, and Risk-Benefit Assessments

Author Affiliations
  • 1University Center for Human Values, Princeton University, New Jersey
JAMA Pediatr. 2013;167(12):1093-1094. doi:10.1001/jamapediatrics.2013.3771

Vaccination programs against rotavirus have the potential to dramatically improve the health of children worldwide. Two licensed rotavirus vaccines currently in use have been shown to be highly effective in reducing the burden and consequences of rotavirus-related disease.1 Recently, a third vaccine in late-stage development in India has shown positive results in a large clinical trial. Its approval would provide another option for global rotavirus vaccination efforts, one likely to be more affordable to developing nations where the vast majority of the approximately 500 000 annual deaths attributable to rotavirus occur.

First Page Preview View Large
First page PDF preview
First page PDF preview
×